These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 26586242

  • 1. Adalimumab: A Review in Chronic Plaque Psoriasis.
    Burness CB, McKeage K.
    Drugs; 2015 Dec; 75(18):2119-30. PubMed ID: 26586242
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
    Papp K, Thaçi D, Marcoux D, Weibel L, Philipp S, Ghislain PD, Landells I, Hoeger P, Kotkin C, Unnebrink K, Seyger M, Williams D.
    Lancet; 2017 Jul 01; 390(10089):40-49. PubMed ID: 28478975
    [Abstract] [Full Text] [Related]

  • 3. Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study.
    Thaçi D, Papp K, Marcoux D, Weibel L, Pinter A, Ghislain PD, Landells I, Hoeger PH, Unnebrink K, Seyger MMB, Williams DA, Rubant S, Philipp S.
    Br J Dermatol; 2019 Dec 01; 181(6):1177-1189. PubMed ID: 31017657
    [Abstract] [Full Text] [Related]

  • 4. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study.
    Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK.
    Health Qual Life Outcomes; 2008 Oct 02; 6():75. PubMed ID: 18831744
    [Abstract] [Full Text] [Related]

  • 5. Adalimumab: in plaque psoriasis.
    Croom KF, McCormack PL.
    Am J Clin Dermatol; 2009 Oct 02; 10(1):43-50. PubMed ID: 19170412
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
    Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.
    Am J Clin Dermatol; 2011 Feb 01; 12(1):51-62. PubMed ID: 21110526
    [Abstract] [Full Text] [Related]

  • 7. Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.
    Papp KA, Yang M, Sundaram M, Jarvis J, Betts KA, Bao Y, Signorovitch JE.
    Value Health; 2018 Jan 01; 21(1):1-8. PubMed ID: 29304933
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
    Leonardi C, Langley RG, Papp K, Tyring SK, Wasel N, Vender R, Unnebrink K, Gupta SR, Valdecantos WC, Bagel J.
    Arch Dermatol; 2011 Apr 01; 147(4):429-36. PubMed ID: 21173304
    [Abstract] [Full Text] [Related]

  • 10. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
    Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K.
    N Engl J Med; 2015 Jul 09; 373(2):136-44. PubMed ID: 26154787
    [Abstract] [Full Text] [Related]

  • 11. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study.
    Asahina A, Nakagawa H, Etoh T, Ohtsuki M, Adalimumab M04-688 Study Group.
    J Dermatol; 2010 Apr 09; 37(4):299-310. PubMed ID: 20507398
    [Abstract] [Full Text] [Related]

  • 12. Adalimumab for treating childhood plaque psoriasis: a clinical trial evaluation.
    Di Lernia V.
    Expert Opin Biol Ther; 2017 Dec 09; 17(12):1553-1556. PubMed ID: 28829204
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB.
    J Am Acad Dermatol; 2017 Mar 09; 76(3):418-431. PubMed ID: 28057361
    [Abstract] [Full Text] [Related]

  • 14. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, Bianchi L, Chimenti S.
    J Am Acad Dermatol; 2007 Aug 09; 57(2):269-75. PubMed ID: 17574299
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB.
    J Am Acad Dermatol; 2017 Mar 09; 76(3):405-417. PubMed ID: 28057360
    [Abstract] [Full Text] [Related]

  • 16. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.
    Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Camez A.
    Br J Dermatol; 2008 Mar 09; 158(3):549-57. PubMed ID: 18047521
    [Abstract] [Full Text] [Related]

  • 17. Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis.
    Leonardi C, Papp K, Strober B, Thaçi D, Warren RB, Tyring S, Arikan D, Karunaratne M, Valdecantos WC.
    Br J Dermatol; 2019 Jan 09; 180(1):76-85. PubMed ID: 30169904
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of Adalimumab Compared With Methotrexate or Placebo Stratified by Baseline BMI in a Randomized Placebo-Controlled Trial in Patients With Psoriasis.
    Prussick R, Unnebrink K, Valdecantos WC.
    J Drugs Dermatol; 2015 Aug 09; 14(8):864-8. PubMed ID: 26267731
    [Abstract] [Full Text] [Related]

  • 19. Adalimumab in Chronic Plaque Psoriasis: A Clinical Guide.
    Wu JJ, Valdecantos WC.
    J Drugs Dermatol; 2017 Aug 01; 16(8):779-790. PubMed ID: 28809993
    [Abstract] [Full Text] [Related]

  • 20. Adalimumab in children and adolescents with severe plaque psoriasis: a safety evaluation.
    Zangrilli A, Bavetta M, Bianchi L.
    Expert Opin Drug Saf; 2020 Apr 01; 19(4):433-438. PubMed ID: 32250180
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.